Clinical trials: Resectable Pancreatic Adenocarcinoma
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
This phase I/II study tests how well zimberelimab and quemliclustat work in combination with chemotherapy (mFOLFIRINOX) in treating patients pancreatic adenocarcinoma that may or may not be able to be removed by surgery…
- Trial name
- NCT05688215
- Testing
- Biospecimen Collection, Computed Tomography, Core Biopsy
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma
- Trial name
- NCT01010126
- Testing
- Bevacizumab, Temsirolimus
- Where
- 61 sites in United States, Canada
- Volunteers
- 252 people
- Sponsor
- National Cancer Institute (NCI)
Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma
A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC
To explore safety and efficacy of neoantigen personalized mRNA vaccines AK154 monotherapy or in combination with AK104/AK112 and sequential mFOLFIRINOX regime in Resected PDAC
- Trial name
- NCT06913218
- Testing
- AK154, Cadonilimab, Ivonescimab (SMT112 or AK112) Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Akeso
Stage III Pancreatic Cancer, Pancreatic Adenocarcinoma Non-resectable
Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer
This clinical trial compares the effect of malnutrition screening and dietary intervention to standard nutrition care on patients with pancreatic cancer that cannot be removed by surgery (unresectable).
- Trial name
- NCT06090916
- Testing
- Best Practice, Dietary Intervention, Medical Chart Review
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Pancreas Cancer
NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer
The aim of this study is to test the additional value of neoadjuvant chemotherapy to the standard treatment for resectable pancreatic cancer (surgery + adjuvant chemotherapy).
- Trial name
- NEOPAC (NCT01521702)
- Testing
- Neoadjuvant chemotherapy, surgery and Adjuvant chemotherapy
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Institut Paoli-Calmettes
Locally Advanced Pancreatic Adenocarcinoma, Chemotherapy Effect
Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)
This is a Norwegian prospective observational study that evaluates the resectability rate in patients with borderline resectable and locally advanced pancreatic cancer who received neoadjuvant chemotherapy in a population based…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Chemotherapy Effect, Borderline Resectable Pancreatic Adenocarcinoma, Pancreatectomy
- Trial name
- NCT04423731
- Testing
- Folfirinox
- Where
- Norway
- Volunteers
- 251 people
- Sponsor
- Oslo University Hospital
Pancreatic Ductal Adenocarcinoma
Predictors for Low Rates of Surgical Resection in Elderly Patients With Resectable Pancreatic Ductal Adenocarcinoma
More and more older adults are diagnosed with pancreatic ductal adenocarcinoma (PDAC), but the rate of surgical resection in patients with resectable tumour is still low.
- Trial name
- NCT06344299
- Testing
- potential predictors
- Where
- China
- Volunteers
- 5,302 people
- Sponsor
- Fudan University
Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Cancer
Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
This study is a single-arm, phase I trial, up to 16 participants with resectable PDA. The study will examine the efficacy of the mutant IDH1 inhibitor ivosidenib, in conjunction with standard-of-care mFOLFIRINOX in the…
- Trial name
- NCT05209074
- Testing
- Ivosidenib, mFOLFIRINOX
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Case Comprehensive Cancer Center
Pancreatic Cancer, Resectable Pancreatic Adenocarcinoma
Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1
Oesogastric and pancreatic adenocarcinomas are poor-prognosis cancers. Incidence of pancreatic cancer drastically increases to such an extent that it will become the second cause of cancer's mortality by 2030.
- Conditions
- Pancreatic Cancer, Resectable Pancreatic Adenocarcinoma, Adenocarcinoma, Resectable Esophageal Cancer
- Trial name
- HEPATOXALI (NCT06649474)
- Testing
- assess the serum HMGB1 concentrations before and after an oxaliplatin-based chemotherapy
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Clermont-Ferrand
Resectable Pancreatic Duct Adenocarcinoma
Prospective Cohort of Patients Treated Using Neoadjuvant Modified FOLFIRINOX 6 Cycles for Potentially Resectable Pancreatic Duct Adenocarcinoma, Candidate for Participation in the PANACHE02 Clinical Trial
The aim of our study is to build up biological, radiological and tissue collections so as to identify, at the time of diagnosis of pancreatic adenocarcinoma, multifactorial factors and/or biomarkers (tissue, plasma, radiomic)…
- Trial name
- PANACHE02-SC (NCT07034703)
- Where
- France
- Volunteers
- 820 people
- Sponsor
- University Hospital, Rouen
Pancreatic Adenocarcinoma
Diffusion MRI for Pancreatic Adenocarcinoma
The detection of small liver metastases represents a major challenge during the staging process of patients with pancreatic adenocarcinoma.
- Trial name
- PANDA (NCT02896946)
- Testing
- Diffusion-weighted nuclear magnetic resonance imaging
- Volunteers
- 118 people
- Sponsor
- Hospices Civils de Lyon
Pancreatic Cancer
Margin-Intense Combo Therapy in Pts w/Potentially Resectable Pancreatic Cancer
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT01025882
- Testing
- gemcitabine hydrochloride, stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Texas Southwestern Medical Center
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Pancreatic Adenocarcinoma
Borderline Resectable or Resectable or Advanced Pancreatic Adenocarcinoma
Observational study of the Clinical Practice in patients with Borderline resectable or resectable or advanced pancreatic adenocarcinoma.
- Trial name
- NCT03266757
- Volunteers
- 200 people
- Sponsor
- Hellenic Society of Medical Oncology
Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
The objective of this research is to find out what effects (good and bad), the sequence of Gemcitabine - Abraxane (nab-Paclitaxel) followed by mFOLFIRINOX, the standard chemotherapy for pancreatic cancer, has on participants and…
- Conditions
- Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
- Trial name
- NCT05825066
- Testing
- Nab paclitaxel, Gemcitabine, Radiological Assessments
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Wake Forest University Health Sciences
Pancreas, Adenocarcinoma
Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma
This is a multicenter, open label, randomized, phase 2b study, designed to evaluate the safety and efficacy of patients with locally advanced pancreatic adenocarcinoma following intratumoral administration of BC-819 and…
- Trial name
- LAPC-BC-819 (NCT01413087)
- Testing
- Biological/Vaccine: BC-819
- Where
- 9 sites in United States, Israel
- Volunteers
- 12 people
- Sponsor
- Anchiano Therapeutics Israel Ltd.
Pancreatic Neoplasms
Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia
The purpose of this study is to determine the safest dose of the study drug Vitamin E Delta-tocotrienol, how often it should be taken, and how well people with pancreatic tumors tolerate Vitamin E Delta-tocotrienol.
- Trial name
- NCT00985777
- Testing
- Vitamin E δ-Tocotrienol
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma
The application of immunotherapeutic strategies that target the most potent antigen presenting cell, the dendritic cell (DC), are likely to substantially increase the magnitude of the anti-tumor immune response.
- Trial name
- NCT00600002
- Testing
- GM-CSF
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Edward Nelson
Pancreatic Adenocarcinoma, Borderline Resectable Adenocarcinoma of the Head of the Pancrease
Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer
This randomized phase II trial studies how well combination chemotherapy (mFOLFIRINOX) with or without hypofractionated radiation therapy before surgery works in patients with pancreatic cancer that can be removed by surgery.
- Trial name
- NCT02839343
- Testing
- radiation therapy, surgery, mFOLFIRINOX
- Where
- 155 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Carcinoma, Pancreatic Ductal
Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy
Radical surgical resection is the only curative treatment option for pancreatic cancer, but borderline resectable tumors have a high probability of incomplete exeresis.
- Trial name
- PF-BARNA (NCT05489458)
- Testing
- Resection, No Resection
- Volunteers
- 100 people
- Sponsor
- BUSQUETS, JULI